Pfizer Inc
$ 27.14
0.30%
24 Feb - close price
- Market Cap 153,855,246,000 USD
- Current Price $ 27.14
- High / Low $ 27.42 / 27.08
- Stock P/E 19.90
- Book Value 16.32
- EPS 1.36
- Next Earning Report 2026-04-28
- Dividend Per Share $1.72
- Dividend Yield 6.45 %
- Next Dividend Date 2026-03-06
- ROA 0.05 %
- ROE 0.09 %
- 52 Week High 27.94
- 52 Week Low 19.50
About
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Analyst Target Price
$28.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-03 | 2025-11-04 | 2025-08-05 | 2025-04-29 | 2025-02-04 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-01-30 | 2023-10-31 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 0.66 | 0.87 | 0.78 | 0.92 | 0.63 | 1.06 | 0.6 | 0.82 | 0.1 | -0.17 | 0.67 | 1.23 |
| Estimated EPS | 0.57 | 0.63 | 0.57 | 0.67 | 0.46 | 0.61 | 0.46 | 0.51 | -0.18 | -0.34 | 0.58 | 0.99 |
| Surprise | 0.09 | 0.24 | 0.21 | 0.25 | 0.17 | 0.45 | 0.14 | 0.31 | 0.28 | 0.17 | 0.09 | 0.24 |
| Surprise Percentage | 15.7895% | 38.0952% | 36.8421% | 37.3134% | 36.9565% | 73.7705% | 30.4348% | 60.7843% | 155.5556% | 50% | 15.5172% | 24.2424% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.73 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-06 | 2025-12-01 | 2025-09-02 | 2025-06-13 | 2025-03-07 | 2024-12-02 | 2024-09-03 | 2024-06-14 | 2024-03-01 | 2023-12-04 |
| Amount | $0.43 | $0.43 | $0.43 | $0.43 | $0.43 | $0.42 | $0.42 | $0.42 | $0.42 | $0.41 |
Next Dividend Records
| Dividend per share (year): | $1.72 |
| Dividend Yield | 6.45% |
| Next Dividend Date | 2026-03-06 |
| Ex-Dividend Date | 2026-01-23 |
Recent News: PFE
2026-02-25 05:51:14
The Antipyretics Market is projected for substantial growth between 2026 and 2033, driven by increasing demand and innovation from key players like Pfizer, GlaxoSmithKline, and Sanofi. A new report by Coherent Market Insights provides a comprehensive analysis of market trends, drivers, challenges, and competitive landscape, offering actionable strategies for industry leaders. The report details market segmentation by product type, application, end-user, and region, and includes a competitive analysis of major companies.
2026-02-24 18:25:59
Pfizer's oral cancer drug Braftovi has received full FDA approval for a first-line combination regimen to treat colorectal cancer. This decision is based on clinical data and marks a significant regulatory milestone for the drug developed in partnership with Ono Pharmaceutical. The approval broadens Braftovi's potential use in cancer treatment.
2026-02-24 16:52:41
Lantheus Holdings Inc. (NASDAQ: LNTH) has experienced a significant stock selloff, leading investors to question if it's a breakout setup or a value trap. The company, focused on specialized US imaging and diagnostics, has seen high volatility due to earnings commentary, guidance updates, and broader market shifts in biotech. Analysts generally maintain positive ratings, with discussions centering on growth quality versus concentration risk, valuation compared to peers, and the potential of its pipeline and partnerships.
2026-02-24 14:29:00
The U.S. FDA has granted full approval to Pfizer's BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adults with BRAF V600E mutant metastatic colorectal cancer. This approval is based on global Phase 3 BREAKWATER trial results, showing a significant reduction in death and disease progression. The BRAFTOVI combination regimen is the only approved targeted therapy for first-line BRAF-V600E mutant mCRC, establishing a new standard of care.
2026-02-24 13:53:14
Protalix Biotherapeutics, Inc. has reached a new 52-week high of $3.19, reflecting strong performance in the pharmaceuticals and biotechnology sector. The company's stock price has increased by 163.87% over the past year, significantly outperforming the S&P 500. It maintains a price-to-earnings ratio of 27.00 and a market capitalization of $246 million.
2026-02-24 13:51:52
Kyntra Bio Inc. shares fluctuated after announcing Phase 1b/2 study data for FG-3246 in combination with enzalutamide for metastatic castration-resistant prostate cancer, showing a 21% composite response rate. William Blair issued a "Market Perform" rating, encouraged by the initial results but advising caution due to the early stage and competitive market. The study highlighted a median radiographic progression-free survival of 10.1 months in a sub-group of patients.
